vector-based gene therapy (NIH)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namevector-based gene therapy (NIH)
Drug Alias NameTIL cell gene therapy (NIH)IL-2 gene therapy (NIH)
ClassificationBiologics
Mechanisms of ActionTumor necrosis factor agonistsIL2 gene transference
TargetsInterleukin-2Tumor necrosis factor
Therapy Area/IndicationsColonic NeoplasmsCarcinoma, Renal CellMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of Health
Active IndicationsN/A
Inactive IndicationsColonic NeoplasmsCarcinoma, Renal CellMelanoma

Other Information

ATC CodeN/A
Related LinksN/A